Role of iNKT Cells in Autoimmunity and Atherosclerosis

iNKT 细胞在自身免疫和动脉粥样硬化中的作用

基本信息

  • 批准号:
    7500836
  • 负责人:
  • 金额:
    $ 38.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-25 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Atherosclerosis is a chronic inflammatory disease associated with the activation of both innate and adaptive immune responses. Minority populations and young women with systemic lupus erythematosus are particularly prone to the development of atherosclerosis. Recently, a unique group of T lymphocytes, called invariant natural killer T (iNKT) cells, have been implicated in atherogenesis and lupus. This Project will test the hypothesis that iNKT cells are chronically activated during hyperlipidemia and that this conversion is uniquely involved in regulating and/or modulating an inflammatory response that exacerbates atherosclerosis and dysregulates immunity. This hypothesis is based on key preliminary studies demonstrating that (a) iNKT cell numbers and functions are altered in spontaneously hyperlipidemic apoE-deficient (apoE-/-) mice; (b) iNKT cells of apoE-/- mice express phenotypic markers distinct from wild type iNKT cells, suggesting activation; (c) absence of iNKT cells in apoE-/- mice reduces atherosclerosis but aggravates lupus; and (d) specific activation of iNKT cells in vivo is proatherogenic but protects against lupus. Based on these findings, the overall objective of this Project is to characterize the immunoregulatory mechanism(s) by which iNKT cells promote lesion formation in the artery wall. Our specific aims are to: (1) investigate the effects of hyperlipidemia and atherosclerosis on iNKT cell numbers and functions in apoE-/- mice; (2) investigate the role of cytokine production by iNKT cells and subsequent immune activation in atherosclerosis and (3) determine the role of iNKT cells in lupus-accelerated atherosclerosis. Relevance to Public Health: Coronary heart disease associated with atherosclerosis is the primary cause of mortality in the United States. At extremely high risk for suffering a fatal cardiac event are young women with lupus. Lupus-accelerated atherosclerosis is independent of cholesterol levels and is thought to be largely associated with autoimmune dysregulation. iNKT cells represent some of the most potent immune regulators. Therefore, understanding their significance in lupus and atherosclerosis will provide valuable insights for the future generation of immunotherapy to treat both lupus and heart disease.
描述(由申请人提供):动脉粥样硬化是一种与先天和适应性免疫反应激活相关的慢性炎症性疾病。少数民族和年轻女性系统性红斑狼疮患者特别容易发展为动脉粥样硬化。最近,一种独特的T淋巴细胞群,称为不变自然杀伤T (iNKT)细胞,被认为与动脉粥样硬化和狼疮有关。该项目将验证iNKT细胞在高脂血症期间被慢性激活的假设,并且这种转化独特地参与调节和/或调节炎症反应,从而加剧动脉粥样硬化和免疫失调。这一假设是基于关键的初步研究,这些研究表明:(a)自发性高脂血症apoE-/-缺陷小鼠的iNKT细胞数量和功能发生改变;(b) apoE-/-小鼠的iNKT细胞表达与野生型iNKT细胞不同的表型标记,提示活化;(c) apoE-/-小鼠中iNKT细胞的缺失减少了动脉粥样硬化,但加重了狼疮;(d)体内iNKT细胞的特异性激活是致动脉粥样硬化,但对狼疮有保护作用。基于这些发现,本项目的总体目标是表征iNKT细胞促进动脉壁病变形成的免疫调节机制。我们的具体目标是:(1)研究高脂血症和动脉粥样硬化对apoE-/-小鼠iNKT细胞数量和功能的影响;(2)研究iNKT细胞产生细胞因子和随后的免疫激活在动脉粥样硬化中的作用;(3)确定iNKT细胞在狼疮加速动脉粥样硬化中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMY S MAJOR其他文献

AMY S MAJOR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMY S MAJOR', 18)}}的其他基金

Investigating mechanisms of oxidized phospholipid-mediated dysregulation of regulatory T cells in atherosclerosis
研究动脉粥样硬化中氧化磷脂介导的调节性 T 细胞失调的机制
  • 批准号:
    10648711
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10450688
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10664909
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
  • 批准号:
    10259917
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10029497
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10609478
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
  • 批准号:
    10380090
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    10640277
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    9791561
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
  • 批准号:
    10413896
  • 财政年份:
    2019
  • 资助金额:
    $ 38.38万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 38.38万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 38.38万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 38.38万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 38.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了